WO2003013497A1 - Compositions having effects of preventing or ameliorating conditions or diseases caused by brain hypofunction - Google Patents

Compositions having effects of preventing or ameliorating conditions or diseases caused by brain hypofunction Download PDF

Info

Publication number
WO2003013497A1
WO2003013497A1 PCT/JP2002/000671 JP0200671W WO03013497A1 WO 2003013497 A1 WO2003013497 A1 WO 2003013497A1 JP 0200671 W JP0200671 W JP 0200671W WO 03013497 A1 WO03013497 A1 WO 03013497A1
Authority
WO
WIPO (PCT)
Prior art keywords
preventing
effects
compositions
diseases caused
ameliorating conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2002/000671
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
Kengo Akimoto
Hiroshi Kawashima
Yoshiko Ono
Hiroshige Okaichi
Youko Okaichi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suntory Ltd
Original Assignee
Suntory Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=19066953&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2003013497(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to CA2456049A priority Critical patent/CA2456049C/en
Priority to KR1020047001544A priority patent/KR101989390B1/ko
Priority to AT02716453T priority patent/ATE520395T1/de
Priority to US10/485,456 priority patent/US10744146B2/en
Priority to EP02716453A priority patent/EP1419768B1/en
Application filed by Suntory Ltd filed Critical Suntory Ltd
Priority to KR1020177026429A priority patent/KR20170109693A/ko
Priority to DK02716453.2T priority patent/DK1419768T3/da
Publication of WO2003013497A1 publication Critical patent/WO2003013497A1/ja
Anticipated expiration legal-status Critical
Priority to AU2008201045A priority patent/AU2008201045B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
    • A23D9/007—Other edible oils or fats, e.g. shortenings or cooking oils characterised by ingredients other than fatty acid triglycerides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
    • A23D9/007—Other edible oils or fats, e.g. shortenings or cooking oils characterised by ingredients other than fatty acid triglycerides
    • A23D9/013—Other fatty acid esters, e.g. phosphatides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
PCT/JP2002/000671 2001-08-02 2002-01-29 Compositions having effects of preventing or ameliorating conditions or diseases caused by brain hypofunction Ceased WO2003013497A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
DK02716453.2T DK1419768T3 (da) 2001-08-02 2002-01-29 Præparater med virkning til forebyggelse eller bedring af tilstande eller sygdomme forårsaget af hjernehypofunktion
KR1020047001544A KR101989390B1 (ko) 2001-08-02 2002-01-29 뇌기능 저하에 기인하는 증상이나 질환의 예방 또는 개선작용을 가지는 조성물
AT02716453T ATE520395T1 (de) 2001-08-02 2002-01-29 Zusammensetzungen zur prävention oder linderung von zuständen oder erkrankungen, die durch unterfunktion des gehirns verursacht werden
US10/485,456 US10744146B2 (en) 2001-08-02 2002-01-29 Composition having effects of preventing or ameliorating conditions or diseases caused by brain hypofunction
EP02716453A EP1419768B1 (en) 2001-08-02 2002-01-29 Compositions having effects of preventing or ameliorating conditions or diseases caused by brain hypofunction
CA2456049A CA2456049C (en) 2001-08-02 2002-01-29 Compositions having effects of preventing or ameliorating conditions or diseases caused by brain hypofunction
KR1020177026429A KR20170109693A (ko) 2001-08-02 2002-01-29 뇌기능 저하에 기인하는 증상이나 질환의 예방 또는 개선 작용을 가지는 조성물
AU2008201045A AU2008201045B2 (en) 2001-08-02 2008-03-05 Compositions having effects of preventing or ameliorating conditions or diseases caused by brain hypofunction

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001-235519 2001-08-02
JP2001235519A JP2003048831A (ja) 2001-08-02 2001-08-02 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物

Publications (1)

Publication Number Publication Date
WO2003013497A1 true WO2003013497A1 (en) 2003-02-20

Family

ID=19066953

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/000671 Ceased WO2003013497A1 (en) 2001-08-02 2002-01-29 Compositions having effects of preventing or ameliorating conditions or diseases caused by brain hypofunction

Country Status (13)

Country Link
US (1) US10744146B2 (enExample)
EP (1) EP1419768B1 (enExample)
JP (1) JP2003048831A (enExample)
KR (2) KR101989390B1 (enExample)
CN (2) CN101336913A (enExample)
AT (1) ATE520395T1 (enExample)
AU (1) AU2008201045B2 (enExample)
CA (1) CA2456049C (enExample)
CY (1) CY1111808T1 (enExample)
DK (1) DK1419768T3 (enExample)
ES (1) ES2369074T3 (enExample)
PT (1) PT1419768E (enExample)
WO (1) WO2003013497A1 (enExample)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004084882A1 (en) * 2003-03-27 2004-10-07 Suntory Limited Use of arachidonic acid for normalization of infradian rhythm
WO2005018632A1 (en) * 2003-08-18 2005-03-03 Btg International Limited Treatment of neurodegenerative conditions
GB2442161A (en) * 2003-08-18 2008-03-26 Btg Int Ltd Treatment of neurodegenerative conditions
GB2442164A (en) * 2003-08-18 2008-03-26 Btg Int Ltd Treatment of neurodegenerative conditions
EP1713463A4 (en) * 2004-01-19 2009-03-18 Martek Biosciences Corp REELIN DYSFUNCTION OR DICTION AND ASSOCIATED TECHNIQUES
CN1867328B (zh) * 2003-08-18 2010-12-29 英国技术集团国际有限公司 脂类甘油酯用于制备治疗神经变性状况的药物的应用
US8202907B2 (en) 2004-09-17 2012-06-19 Suntory Holdings Limited Composition with preventive or improvement effect on symptoms or diseases associated with stress-induced behavior disorders
US8372812B2 (en) 2009-02-26 2013-02-12 Aker Biomarine Asa Phospholipid and protein tablets
US8383677B2 (en) 2006-12-28 2013-02-26 Suntory Holdings Limited Nerve-regenerating agent
US8697138B2 (en) 2007-03-28 2014-04-15 Aker Biomarine As Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders
US9028877B2 (en) 2007-03-28 2015-05-12 Aker Biomarine Antarctic As Bioeffective krill oil compositions
US9168241B2 (en) 2005-06-30 2015-10-27 Suntory Holdings Limited Compositions ameliorating a reduced diurnal activity and/or depressive symptoms
US9867856B2 (en) 2014-01-10 2018-01-16 Aker Biomarine Antarctic As Phospholipid compositions and their preparation
US10456412B2 (en) 2015-02-11 2019-10-29 Aker Biomarine Antarctic As Lipid extraction processes
US10704011B2 (en) 2013-06-14 2020-07-07 Aker Biomarine Antarctic As Lipid extraction processes
US10744146B2 (en) 2001-08-02 2020-08-18 Suntory Holdings Limited Composition having effects of preventing or ameliorating conditions or diseases caused by brain hypofunction
US10864223B2 (en) 2015-02-11 2020-12-15 Aker Biomarine Antarctic As Lipid compositions

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070004670A1 (en) * 1998-07-31 2007-01-04 Richard Wurtman Compositions containing citicoline, and methods of use thereof
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
WO2004028529A1 (en) * 2002-09-24 2004-04-08 Suntory Limited Composition with effects of decline prevention, improvement or enhancement of normal responses of cognitive abilities of a healthy person
AU2004223980B2 (en) 2003-03-27 2010-11-11 Suntory Holdings Limited Lipid-improving agent and composition containing lipid-improving agent
GB0311081D0 (en) 2003-05-14 2003-06-18 Btg Internat Limted Treatment of neurodegenerative conditions
JP4522075B2 (ja) * 2003-10-29 2010-08-11 サントリーホールディングス株式会社 血管の老化に起因する症状あるいは疾患の予防又は改善作用を有する組成物
TWI365716B (en) * 2003-12-02 2012-06-11 Suntory Holdings Ltd Oil or fat and oil compositions containing phospholipids and a long-chain polyunsaturated fatty acid supply compound, and food using same
CN1954079B (zh) 2004-03-01 2012-08-08 三得利控股株式会社 含有作为构成要素的长链高不饱和脂肪酸的磷脂质的制造方法及其应用
CA2575671C (en) 2004-08-12 2013-10-22 Suntory Limited Method for polyunsaturated fatty acid production using novel cell preservation technique
JP2006083136A (ja) * 2004-09-17 2006-03-30 Suntory Ltd ストレスに起因する脳機能の低下およびそれに伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP4849806B2 (ja) 2005-02-08 2012-01-11 日本水産株式会社 新規な菌体処理方法を用いた高度不飽和脂肪酸の製造方法
US8241868B2 (en) 2005-02-08 2012-08-14 Nippon Suisan Kaisha, Ltd. Production of polyunsaturated fatty acids using cell treatment method
GB0504362D0 (en) 2005-03-02 2005-04-06 Btg Int Ltd Cytokine modulators
PT1888081T (pt) * 2005-05-23 2017-03-01 Massachusetts Inst Technology Composições contendo pufa e seus métodos de utilização
JP5697293B2 (ja) * 2005-06-30 2015-04-08 サントリーホールディングス株式会社 器質的脳障害に起因する高次脳機能の低下に対する改善作用を有する組成物
AU2006299665B2 (en) * 2005-09-30 2012-12-13 Nestec S.A. Methods and compositions for improving cognitive function
EP1772146A1 (en) * 2005-10-03 2007-04-11 Neuropharma, S.A. Polyunsaturated fatty acids as bace inhibitors
DE102005058369A1 (de) * 2005-12-06 2007-06-14 Lts Lohmann Therapie-Systeme Ag Ungesättigte Fettsäuren als Thrombin-Inhibitoren
JP5050195B2 (ja) * 2006-02-14 2012-10-17 国立大学法人 岡山大学 神経細胞分化誘導剤
KR20090003148A (ko) * 2006-04-03 2009-01-09 액세라인크 나이와 관련된 기억 손상의 치료를 위한 케톤 생성조성물의 용도
AU2008269989B2 (en) * 2007-06-29 2014-02-27 Dsm Ip Assets B.V. Production and purification of esters of polyunsaturated fatty acids
JP2009019025A (ja) * 2007-07-13 2009-01-29 Suntory Ltd 非ヒト動物の老化又は痴呆に伴う疾患又は症状の改善剤
AU2008282130B2 (en) 2007-07-31 2014-08-21 Cerecin Inc. Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
EP2303036A1 (en) 2008-07-03 2011-04-06 Accera, Inc. Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders
JP2009219500A (ja) * 2009-06-22 2009-10-01 Suntory Holdings Ltd 血管の老化に起因する症状あるいは疾患の予防又は改善作用を有する組成物
JP2011136948A (ja) * 2009-12-28 2011-07-14 Nisshin Oillio Group Ltd うつ病又はうつ状態の予防又は治療用油脂組成物
US9549937B2 (en) 2013-12-05 2017-01-24 Burvia, LLC. Composition containing phospholipid-DHA and folate
US9216199B2 (en) 2013-12-05 2015-12-22 Buriva, LLC Nutritional supplement containing phospholipid-DHA derived from eggs
US9610302B2 (en) 2013-12-05 2017-04-04 Buriva, LLC. Composition containing phospholipid-DHA and B vitamins
US9233114B2 (en) 2013-12-05 2016-01-12 Buriva, LLC Dietary supplement containing phospholipid-DHA derived from eggs
CN106659782B (zh) 2014-05-23 2021-11-09 塞尔德克斯医疗公司 一种用于嗜酸性粒细胞或肥大细胞相关病症治疗的抗体
JP6095615B2 (ja) * 2014-07-22 2017-03-15 サントリーホールディングス株式会社 器質的脳障害に起因する高次脳機能の低下に対する改善作用を有する組成物
JP2016172770A (ja) * 2016-06-29 2016-09-29 サントリーホールディングス株式会社 器質的脳障害に起因する高次脳機能の低下に対する改善作用を有する組成物
US10456368B2 (en) 2016-09-26 2019-10-29 Garrett E. Wdowin Compositions for mitigating brain trauma and methods thereof
CN110747239B (zh) * 2019-11-26 2021-06-22 瞿瀚鹏 富含Sn-2位ARA的微生物油脂及其制备方法和应用

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB111282A (en) 1916-11-10 Ets De Dion Bouton Improvements in or relating to Roller Bearings.
US4668704A (en) * 1982-08-09 1987-05-26 Regents Of The University Of California Method for protecting and healing gastro-duodenal mucosa and the liver of mammals
US4526902A (en) * 1983-10-24 1985-07-02 Century Laboratories, Inc. Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions
GB8601915D0 (en) 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
JPS63297342A (ja) 1987-05-28 1988-12-05 Nisshin Oil Mills Ltd:The 合成油脂ならびにこれを含有する脂肪乳剤輸液および経腸栄養剤
US5198468A (en) * 1987-06-24 1993-03-30 Efamol Holdings Plc Essential fatty acid composition
GB8714772D0 (en) 1987-06-24 1987-07-29 Efamol Ltd Essential fatty acid compositions
US5658767A (en) 1991-01-24 1997-08-19 Martek Corporation Arachidonic acid and methods for the production and use thereof
GB9224809D0 (en) 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
GB9300125D0 (en) * 1993-01-06 1993-03-03 Scotia Holdings Plc Compositions containing esters of unsaturated fatty acids
AU683027B2 (en) * 1993-01-27 1997-10-30 Scotia Holdings Plc Triglycerides
JP3467794B2 (ja) 1993-03-09 2003-11-17 日本油脂株式会社 学習能向上剤
WO1994028891A1 (en) 1993-06-04 1994-12-22 Martek Biosciences Corporation Method of treating coronary vascular disease using docosahexaenoic acid
CA2596241C (en) 1993-06-09 2011-04-19 Martek Biosciences Corporation Methods and pharmaceutical compositions useful for treating neurological disorders
ES2118629T3 (es) 1994-10-05 1998-09-16 Milupa Gmbh & Co Kg Mezcla de grasas conteniendo fosfolipidos con acidos grasos lcp
JPH08143454A (ja) 1994-11-17 1996-06-04 Kanagawa Kagaku Kenkyusho:Kk 神経成長因子産生増強剤
GB9423625D0 (en) 1994-11-23 1995-01-11 Scotia Holdings Plc Fortified fruit juice
US5583019A (en) * 1995-01-24 1996-12-10 Omegatech Inc. Method for production of arachidonic acid
JPH08214891A (ja) 1995-02-17 1996-08-27 Osaka City 高度不飽和脂肪酸含有トリグリセリドを含む油脂の製造方法
EP0831805A1 (en) 1995-06-07 1998-04-01 Martek Biosciences Corporation Methods for controlling highly unsaturated fatty acid content in various tissues
JPH0923817A (ja) 1995-07-07 1997-01-28 Nisshin Oil Mills Ltd:The 油脂含有飲食物
JPH0930962A (ja) 1995-07-21 1997-02-04 Nisshin Oil Mills Ltd:The 医療用油脂含有組成物
US6200624B1 (en) 1996-01-26 2001-03-13 Abbott Laboratories Enteral formula or nutritional supplement containing arachidonic and docosahexaenoic acids
CN1058845C (zh) 1996-01-31 2000-11-29 高世虎 强化营养豆奶粉
GB9617847D0 (en) 1996-08-27 1996-10-09 Scotia Holdings Plc Fatty acid treatment
JP4034370B2 (ja) * 1996-09-27 2008-01-16 雪印乳業株式会社 脳機能改善剤及び栄養組成物
JP4633204B2 (ja) 1996-10-11 2011-02-16 サントリーホールディングス株式会社 アラキドン酸含有食用油脂およびそれを含有する食品
JPH10155459A (ja) 1996-11-27 1998-06-16 Suntory Ltd アスタキサンチン含有飲食物
US6080787A (en) * 1997-02-21 2000-06-27 Abbott Laboratories Methods for reducing the incidence of necrotizing enterocolitis
FR2762993B1 (fr) 1997-05-06 1999-08-13 Inst Rech Biolog Sa Nouvelle utilisation de phospholipides d'origine animale en therapeutique et/ou dietetique
US5902807A (en) * 1997-05-12 1999-05-11 Antti Haapalinna Method for the treatment of mental illness in mammals and a composition therefor
KR100255868B1 (ko) * 1997-06-28 2000-05-01 김영환 2의 보수 복소수 곱셈기
EP0893064B1 (fr) 1997-07-22 2003-01-15 Societe Des Produits Nestle S.A. Composition lipidique pour formule infantile et procédé de préparation
JP2970804B2 (ja) 1997-07-23 1999-11-02 株式会社フジクラ 難燃性シート
US6225444B1 (en) * 1998-02-10 2001-05-01 Protarga, Inc. Neuroprotective peptides and uses thereof
JP4175698B2 (ja) 1998-06-19 2008-11-05 サントリー株式会社 新規なトリグリセリド及びそれを含む組成物
ES2284286T5 (es) * 1998-10-15 2011-01-03 Dsm Ip Assets B.V. Suplementos de pufa.
JP2001031586A (ja) 1999-07-14 2001-02-06 Sunstar Inc 動脈硬化症及び動脈硬化症に起因する疾患の予防又は治療組成物
GB9916536D0 (en) 1999-07-14 1999-09-15 Scarista Limited Nutritional or pharmaceutical compositions
GB9923738D0 (en) 1999-10-07 1999-12-08 Nestle Sa Nutritional composition
US7226916B1 (en) 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
US7208180B2 (en) * 2000-05-08 2007-04-24 N.V. Nutricia Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith
AU2001269375A1 (en) 2000-05-08 2001-11-20 Forskarpatent I Syd Ab Anandamide and structurally related lipids as vanilloid receptor modulators
US20020077355A1 (en) 2000-05-30 2002-06-20 Liao James K. Use of epoxyeicosatrienoic acids in the treatment of cerebrovascular conditions
EP1292288B1 (en) 2000-06-23 2004-09-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem 2-arachidonylglycerol (2-ag) - an inhibitor of tumor necrosis factor -alfa and neuroprotector of brain in closed head injury
GB0016045D0 (en) * 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
WO2002019839A1 (en) 2000-09-07 2002-03-14 University Of Maryland Biotechnology Institute Use of arachidonic acid for enhanced culturing of fish larvae and broodstock
EP1239022B1 (fr) 2001-03-09 2009-05-06 Societe Des Produits Nestle S.A. Huile contenant un ou des acide(s) gras polyinsaturé(s) à longue chaîne issus de biomasse, procédé de Préparation, allment, composition nutritionnelle, cosmétique ou pharmaceutique la contenant
GB0111282D0 (en) 2001-05-09 2001-06-27 Laxdale Ltd Potentiation of therapeutic effects of fatty acids
DK1997498T3 (da) 2001-06-18 2012-07-30 Neptune Technologies & Bioressources Inc Krillekstrakter til forebyggelse og/eller behandling af kardiovaskulære sygdomme
CA2452401C (en) 2001-07-02 2013-02-26 Suntory Limited Process for producing fat comprising triglyceride containing highly unsaturated fatty acid
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
US20040219208A1 (en) * 2001-08-03 2004-11-04 Ryu Kawamura Sustained-release medicines
JP2003113120A (ja) 2001-08-03 2003-04-18 Takeda Chem Ind Ltd 徐放性医薬
US6689810B2 (en) * 2001-08-21 2004-02-10 Cellular Sciences, Inc. Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide
EP1501493B1 (en) 2002-05-03 2009-10-07 Pronova BioPharma Norge AS Use of epa and dha in secondary prevention of strokes
AU2003260967B2 (en) 2002-09-13 2009-12-10 Suntory Holdings Limited Process for production of transesterified oils/fats or triglycerides
GB0221480D0 (en) 2002-09-16 2002-10-23 Laxdale Ltd Treatment of anorexia nervosa (AN) and bulimia
WO2004028529A1 (en) 2002-09-24 2004-04-08 Suntory Limited Composition with effects of decline prevention, improvement or enhancement of normal responses of cognitive abilities of a healthy person
CN101843610A (zh) 2003-03-27 2010-09-29 三得利控股株式会社 花生四烯酸在制备具有使超昼夜节律正常化作用的组合物中的用途
JPWO2004091663A1 (ja) 2003-04-18 2006-07-06 協和醗酵工業株式会社 神経再生薬
FI20060154A7 (fi) 2003-08-18 2006-05-11 Btg Int Ltd Neurogeneratiivisten tilojen hoito
IL158552A0 (en) 2003-10-22 2004-05-12 Enzymotec Ltd Lipids containing omega-3 fatty acids
JP4522075B2 (ja) 2003-10-29 2010-08-11 サントリーホールディングス株式会社 血管の老化に起因する症状あるいは疾患の予防又は改善作用を有する組成物
US20090215896A1 (en) 2004-01-19 2009-08-27 Martek Biosciences Corporation Reelin deficiency or dysfunction and methods related thereto
JP4868199B2 (ja) 2004-09-10 2012-02-01 学校法人鈴鹿医療科学大学 サルビアノール酸ｂを有効成分とする神経幹細胞増殖剤
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP2006083136A (ja) 2004-09-17 2006-03-30 Suntory Ltd ストレスに起因する脳機能の低下およびそれに伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP5697293B2 (ja) 2005-06-30 2015-04-08 サントリーホールディングス株式会社 器質的脳障害に起因する高次脳機能の低下に対する改善作用を有する組成物

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
LIPIDS, vol. 26, 1991, pages 421 - 425
LYNCH, M.A. ET AL.: "Impaired spatial memory in aged rats is associated with alterations in inositol phospholipid metabolism", NEUROREPORT, vol. 5, no. 12, 1994, pages 1493 - 1497, XP002950177 *
LYNCH, M.A. ET AL.: "Impaired spatial memory in aged rats is associated with alterations in inositol phospholipid metabolism", NEUROREPORT, vol. 5, no. 15, 1994, pages 1493 - 1497
WAINWRIGHT, P.E. ET AL.: "Arachidonic acid offsets the effects on mouse brain and behavior of a diet with low (n-6):(n-3) ratio and very high levels of docosahexaenoic acid", J. NUTR., vol. 127, no. 1, 1997, pages 184 - 193, XP002950179 *
WAINWRIGHT, P.E. ET AL.: "Water maze performance is unaffected in artificially reared rats fed diets supplemented with arachidonic acid and docosahexaenoic acid", J. NUTR., vol. 129, no. 5, 1999, pages 1079 - 1089, XP002950178 *

Cited By (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10744146B2 (en) 2001-08-02 2020-08-18 Suntory Holdings Limited Composition having effects of preventing or ameliorating conditions or diseases caused by brain hypofunction
US9782377B2 (en) 2003-03-27 2017-10-10 Suntory Holdings Limited Composition for normalization of infradian rhythm
CN1756544B (zh) * 2003-03-27 2011-07-27 三得利控股株式会社 花生四烯酸在制备具有使超昼夜节律正常化作用的组合物中的用途
WO2004084882A1 (en) * 2003-03-27 2004-10-07 Suntory Limited Use of arachidonic acid for normalization of infradian rhythm
GB2442164B (en) * 2003-08-18 2008-05-21 Btg Int Ltd Treatment of neurodegenerative conditions
GB2442161B (en) * 2003-08-18 2008-05-21 Btg Int Ltd Triglycerides
GB2442164A (en) * 2003-08-18 2008-03-26 Btg Int Ltd Treatment of neurodegenerative conditions
GB2422373B (en) * 2003-08-18 2008-05-21 Btg Int Ltd Treatment of neurodegenerative conditions
GB2442161A (en) * 2003-08-18 2008-03-26 Btg Int Ltd Treatment of neurodegenerative conditions
CN1867328B (zh) * 2003-08-18 2010-12-29 英国技术集团国际有限公司 脂类甘油酯用于制备治疗神经变性状况的药物的应用
EP2324828A1 (en) 2003-08-18 2011-05-25 BTG International Limited Treatment for neurodegenerative conditions
GB2422373A (en) * 2003-08-18 2006-07-26 Btg Int Ltd Treatment of neurodegenerative conditions
WO2005018632A1 (en) * 2003-08-18 2005-03-03 Btg International Limited Treatment of neurodegenerative conditions
EP1713463A4 (en) * 2004-01-19 2009-03-18 Martek Biosciences Corp REELIN DYSFUNCTION OR DICTION AND ASSOCIATED TECHNIQUES
US8367729B2 (en) 2004-09-17 2013-02-05 Suntory Holdings Limited Composition with preventive or improvement effect on symptoms or diseases associated with stress-induced behavior disorders
US8202907B2 (en) 2004-09-17 2012-06-19 Suntory Holdings Limited Composition with preventive or improvement effect on symptoms or diseases associated with stress-induced behavior disorders
US9168241B2 (en) 2005-06-30 2015-10-27 Suntory Holdings Limited Compositions ameliorating a reduced diurnal activity and/or depressive symptoms
US8383677B2 (en) 2006-12-28 2013-02-26 Suntory Holdings Limited Nerve-regenerating agent
US9078905B2 (en) 2007-03-28 2015-07-14 Aker Biomarine Antarctic As Bioeffective krill oil compositions
US8697138B2 (en) 2007-03-28 2014-04-15 Aker Biomarine As Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders
US9034388B2 (en) 2007-03-28 2015-05-19 Aker Biomarine Antartic As Bioeffective krill oil compositions
US9119864B2 (en) 2007-03-28 2015-09-01 Aker Biomarine Antarctic As Bioeffective krill oil compositions
US9028877B2 (en) 2007-03-28 2015-05-12 Aker Biomarine Antarctic As Bioeffective krill oil compositions
US9220735B2 (en) 2007-03-28 2015-12-29 Aker Biomarine Antarctic As Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders
US9320765B2 (en) 2007-03-28 2016-04-26 Aker Biomarine Antarctic As Bioeffective krill oil compositions
US9375453B2 (en) 2007-03-28 2016-06-28 Aker Biomarine Antarctic As Methods for producing bioeffective krill oil compositions
US9644169B2 (en) 2007-03-28 2017-05-09 Aker Biomarine Antarctic As Bioeffective krill oil compositions
US9644170B2 (en) 2007-03-28 2017-05-09 Aker Biomarine Antarctic As Bioeffective krill oil compositions
US9730966B2 (en) 2007-03-28 2017-08-15 Aker Biomarine Antartic As Method of reducing appetite in a human subject comprising administering krill oil composition
US9072752B1 (en) 2007-03-28 2015-07-07 Aker Biomarine Antarctic As Bioeffective krill oil compositions
US9816046B2 (en) 2007-03-28 2017-11-14 Aker Biomarine Antarctic As Bioeffective krill oil compositions
US11865143B2 (en) 2007-03-28 2024-01-09 Aker Biomarine Antarctic As Bioeffective krill oil compositions
US9889163B2 (en) 2007-03-28 2018-02-13 Aker Biomarine Antarctic As Bioeffective krill oil compositions
US10010567B2 (en) 2007-03-28 2018-07-03 Aker Biomarine Antarctic As Bioeffective krill oil compositions
US10543237B2 (en) 2007-03-28 2020-01-28 Aker Biomarine Antarctic As Bioeffective krill oil compositions
US8372812B2 (en) 2009-02-26 2013-02-12 Aker Biomarine Asa Phospholipid and protein tablets
US10704011B2 (en) 2013-06-14 2020-07-07 Aker Biomarine Antarctic As Lipid extraction processes
US11578289B2 (en) 2013-06-14 2023-02-14 Aker Biomarine Antarctic As Lipid extraction processes
US9867856B2 (en) 2014-01-10 2018-01-16 Aker Biomarine Antarctic As Phospholipid compositions and their preparation
US10456412B2 (en) 2015-02-11 2019-10-29 Aker Biomarine Antarctic As Lipid extraction processes
US10864223B2 (en) 2015-02-11 2020-12-15 Aker Biomarine Antarctic As Lipid compositions
US11819509B2 (en) 2015-02-11 2023-11-21 Aker Biomarine Antarctic As Lipid compositions

Also Published As

Publication number Publication date
EP1419768B1 (en) 2011-08-17
CN1561206A (zh) 2005-01-05
KR20040026697A (ko) 2004-03-31
CN101336913A (zh) 2009-01-07
ATE520395T1 (de) 2011-09-15
US20040266874A1 (en) 2004-12-30
US10744146B2 (en) 2020-08-18
CA2456049C (en) 2012-10-16
ES2369074T3 (es) 2011-11-25
EP1419768A4 (en) 2005-07-06
PT1419768E (pt) 2011-10-13
CY1111808T1 (el) 2015-10-07
JP2003048831A (ja) 2003-02-21
KR101989390B1 (ko) 2019-06-14
CA2456049A1 (en) 2003-02-20
AU2008201045B2 (en) 2011-02-17
AU2008201045A1 (en) 2008-04-03
EP1419768A1 (en) 2004-05-19
DK1419768T3 (da) 2011-09-12
KR20170109693A (ko) 2017-09-29

Similar Documents

Publication Publication Date Title
WO2003013497A1 (en) Compositions having effects of preventing or ameliorating conditions or diseases caused by brain hypofunction
HUP0303881A3 (en) Pharmaceutical compositions containing fatty alcohols and fatty acid esters useful for treatment of inflammation
BR0112073A (pt) Combinações terapêuticas de ácidos graxos
ATE292460T1 (de) Zusammenstellungen die aktive stilbenoidverbindungen enthalten zur senkung des triglyceridspiegels
CA2532596A1 (en) Anti-inflammatory formulations
CA2416685A1 (en) Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
WO2000009639A3 (en) Fatty ester combinations
CA2448035A1 (en) New pharmaceutical composition
EP1595539A4 (en) DRUGS TO REDUCE THE SIDE EFFECTS OF RIBAVIRIN INTERFERON COMBINATION THERAPY
CA2362271A1 (en) Essential fatty acids in the prevention of cardiovascular events
EP1666092A3 (en) Drug combination comprising a fatty acid and a uridine compound.
WO2001019356A3 (en) High lipid diet
MA30584B1 (fr) Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
WO2008120711A1 (ja) タミバロテンカプセル剤
UY26303A1 (es) Composiciones farmacéuticas para administración oral y tópica
AU1438699A (en) Fatty acid uninterrupted by a methylene as anti-inflammatory agents in superficial tissues of mammals
WO2001060331A3 (en) Compositions for preventing cellulite in mammalian skin
MXPA04003540A (es) Utilizacion de un copolimero para producir una forma galenica que contiene un peptido o proteina como agente activo.
IL174336A0 (en) Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient
SI1651194T1 (sl) Stabilni farmacevtski sestavki za nadzorovano sproščanje, ki vsebujejo fenofibrat in pravastatin
AU6725300A (en) Non-hygroscopic salts of active ingredients having therapeutical and/or nutritional activities and orally administrable compositions containing same
RU2002120605A (ru) Детский крем
FR2849776B1 (fr) Utilisation d'un extrait aqueux de pepins d'un vegetal du genre cucurbita comme principe actif dans une composition cosmetique et/ou pharmaceutique
WO2001085668A8 (en) Optically active 2-aminotetralin derivatives, the processes for the preparation thereof and the therapeutical use of pharmaceutical compositions containing them
WO2005040176A3 (en) Methods for the preparation of {2-[8,9-dioxo-2,6-diaza-bicyclo[5.2.0]-non-1(7)-en-2-yl]ethyl}phosphonic acid and esters thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA CN KR

Kind code of ref document: A1

Designated state(s): AU CA CN KR US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2456049

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020047001544

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2002716453

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002226763

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 20028192125

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2002716453

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10485456

Country of ref document: US